Author/Authors :
Babaloo, Zohreh Tabriz University of Medical Sciences - Tabriz , Khajir Yeganeh, Reza Tabriz University of Medical Sciences - Tabriz , Farhoodi, Mehdi Tabriz University of Medical Sciences - Tabriz , Baradaran, Behzad Tabriz University of Medical Sciences - Tabriz , Bonyadi, Mohamadreza Tabriz University of Medical Sciences - Tabriz , Aghebati, Leili Tabriz University of Medical Sciences - Tabriz
Abstract :
Background: Effector CD4+ T cell subsets play an important role in Multiple Sclerosis
(MS). Interleukin-27 (IL-27) suppresses Th (Th1, Th2 and Th17) cells and dampens
autoimmunity and tissue inflammation by promoting the generation of Type 1 regulatory
T cells (Tr1). Objective: To identify the relative levels of IL-27 and IL-17A in MS
disease. Method: In a case-control study, venous blood was collected from forty MS
patients and forty-three healthy subjects as control group. Serum levels of IL-27 and IL-
17A were measured by ELISA method. Results: A significant difference between serum
IL-17A concentration in patients (120.68 ± 209.85 pg/ml) and control group (67.26
± 117.76 pg/ml, p=0.016) was found. Serum IL-27 levels of the MS patients (159.7 ±
581.4 pg/ml) were significantly lower than control subjects (180.35 ± 507.84 pg/ml,
p=0.001). Conclusion: Our findings show decreased levels of IL-27 against increasing
IL-17A levels in patients group which may suggest the suppressive role of IL-27 on inflammatory
process of MS.
